[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Fleiner F, Jumah M, Göktas O: Cancer of the external auditory canal-diagnostic and treatment. Indian J Otolaryngol Head Neck Surg; 2009 Dec;61(4):270-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the external auditory canal-diagnostic and treatment.
  • BACKGROUND: Ear squamous cell carcinoma (SCC) is a tumor with a poor prognosis, due to a late initial diagnosis because of a concealment by primarily benign symptoms and due to the unfavorable localization including the infiltration of important structures such as the middle ear, mandibular joint or dura.
  • RESULTS: The treatment involving surgery, radiotherapy and/or chemotherapy yielded a survival rate of 38.3 ± 11.3 months for T1 and a survival rate of 17.0 ± 3.0 months for T2-T4 tumors.
  • CONCLUSION: The prognosis for ear SCC primarily depends on early clinical and histopathological diagnostics and requires a sufficient and standardized staging to determine the therapy involving surgery and radiochemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1977 Oct;87(10 Pt 1):1622-34 [904397.001]
  • [Cites] Laryngoscope. 1976 Mar;86(3):405-15 [1256215.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1215-8 [2233086.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Am J Otol. 1989 Mar;10(2):111-6 [2735381.001]
  • [Cites] Am J Otol. 1988 Sep;9(5):351-6 [3059809.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] J Laryngol Otol. 1985 Sep;99(9):847-50 [4045304.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Laryngol Otol. 2006 Aug;120(8):684-6 [16719955.001]
  • [Cites] Skull Base. 2008 May;18(3):167-72 [18978963.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1984 Oct;9(5):281-99 [6391749.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):687-9 [8499104.001]
  • [Cites] HNO. 2001 Apr;49(4):256-63 [11382105.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):834-7 [12117346.001]
  • [Cites] J Laryngol Otol. 1965 Feb;79:85-119 [14256270.001]
  • (PMID = 23120649.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450079
  • [Keywords] NOTNLM ; Carcinoma of the external auditory canal / Prognosis / Radiation treatment / Squamous cell carcinoma / Surgery
  •  go-up   go-down


2. Almadori G, Bussu F, Navarra P, Galli J, Paludetti G, Giardina B, Maurizi M: Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer; 2006 Jul 15;107(2):328-36
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia.
  • BACKGROUND: It has been previously observed that patients with head and neck squamous cell carcinoma or with laryngeal leucoplakia present a significant reduction in plasma folate levels.
  • METHODS: Forty-three untreated patients affected by glottic laryngeal leucoplakia were enrolled in the Ear, Nose, and Throat Department (Universita Cattolica del Saco Cuore, Rome, Italy).
  • [MeSH-major] Folic Acid / therapeutic use. Laryngeal Neoplasms / drug therapy. Leukoplakia / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Laryngoscopy. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770770.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


3. Sabbatani S, Fulgaro C, Latini G, Burzi M, Manfredi R: Associated actinomycosis and rhinopharyngeal adenocarcinoma during HIV infection: diagnostic and therapeutic issues. Infez Med; 2008 Sep;16(3):164-72
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associated actinomycosis and rhinopharyngeal adenocarcinoma during HIV infection: diagnostic and therapeutic issues.
  • An extremely infrequent episode of nasopharyngeal actinomycosis associated with squamous adenocarcinoma occurred in an HIV-infected male patient with a previous diagnosis of AIDS, treated with combined antiretroviral therapy taken with insufficient adherence, such that a satisfactory immune system recovery (as expressed by a CD4 lymphocyte count persistently above 400 cells/mcl), contrasted with a low-level persistence of detectable HIV viraemia, and enlarged genotypic resistance mutations.
  • Despite appropriate and timely diagnostic assessment carried out with repeated, combined computerized tomography, magnetic resonance imaging, and fiberoptic rhinoscopy with biopsy and histopathologic studies, the final diagnosis of a combined dual infectious-neoplastic pathology occurred only after a demolishing surgical intervention and subsequent pathology studies.
  • Despite proper antimicrobial therapy, and an associated radiotherapy and cytotoxic chemotherapy schedule, rapid dissemination of multiple secondary lesions to the brain rapidly led to our patient's death.
  • The imaging and histopathological diagnostics of the dual illnesses of our HIV-infected patient, and its therapeutic and outcome features, are presented and discussed on the basis of the evidence from the available literature.
  • To the best of our knowledge, this is the first described case of actinomycosis associated with a local, underlying squamous cell adenocarcinoma of the same ear, nose, and throat district in either HIV-infected or HIV-non-infected subjects.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Acquired Immunodeficiency Syndrome / complications. Actinomycosis / complications. Carcinoma, Squamous Cell / complications. Nasopharyngeal Neoplasms / complications. Sinusitis / complications
  • [MeSH-minor] Administration, Inhalation. Anti-Bacterial Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Brain Neoplasms / secondary. Cocaine-Related Disorders / complications. Combined Modality Therapy. Fatal Outcome. Heroin Dependence / complications. Humans. Male. Middle Aged. Patient Compliance. Smoking / adverse effects. Substance Abuse, Intravenous / complications. Tomography, X-Ray Computed


Advertisement
4. LoTempio MM, Wang MB, Sadeghi A: Treatment of advanced oropharyngeal cancers with chemotherapy and radiation. Ear Nose Throat J; 2003 May;82(5):367-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced oropharyngeal cancers with chemotherapy and radiation.
  • We conducted a retrospective chart review of treatment outcomes in 17 adults who had been selected to undergo concomitant chemotherapy and radiation (chemo/XRT) for late-stage oropharyngeal cancers.
  • Of this group, 15 patients completed one to three cycles of chemo/XRT, and the remaining two died during therapy.
  • At the most recent follow-up, 9 of the 17 patients (52.9%) were documented to still be alive; seven patients had earlier died as a result of their primary tumor or a distant metastasis, and one patient had been lost to follow-up after completing treatment.
  • At study's end, the duration of post-treatment survival ranged from 2 to 36 months (mean: 12.5).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Palliative Care / methods
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiation Dosage. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12789762.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Bibas AG, Ward V, Gleeson MJ: Squamous cell carcinoma of the temporal bone. J Laryngol Otol; 2008 Nov;122(11):1156-61
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone.
  • OBJECTIVE: The aim of this study was to present the management and survival data of patients with squamous cell carcinoma of the temporal bone, and to discuss whether extensive surgery improves survival.
  • PATIENTS AND METHODS: Retrospective, case-series review of 17 patients (18 cases) with temporal bone carcinoma (15 primary and three recurrent tumours), over a period of 20 years.
  • Twelve cases of de novo tumour were managed by surgical resection followed by adjuvant radiotherapy in 10 cases, while three such patients were considered incurable from the outset and were given a combination of radiotherapy and chemotherapy.
  • All but one recurrence developed within 12 months of initiating treatment.
  • CONCLUSIONS: A lateral temporal bone resection is adequate treatment for T1 and T2 tumours.
  • For T3 and T4 tumours, a subtotal petrosectomy with parotidectomy followed by post-operative radiotherapy is adequate treatment, as it offers a similar outcome to that of more extensive procedures.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Ear Neoplasms / therapy. Skull Neoplasms / therapy. Temporal Bone
  • [MeSH-minor] Adult. Aged. Ear, Inner. Ear, Middle. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177533.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Takahashi K, Yamamoto Y, Sato K, Sato Y, Takahashi S: Middle ear carcinoma originating from a primary acquired cholesteatoma: a case report. Otol Neurotol; 2005 Jan;26(1):105-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Middle ear carcinoma originating from a primary acquired cholesteatoma: a case report.
  • OBJECTIVES: To describe middle ear carcinoma originating from the matrix of primary acquired cholesteatoma in a 43-year-old man and to discuss the relationship between middle ear carcinoma and cholesteatoma.
  • PATIENT: A 43-year-old man demonstrated symptoms resembling those of cholesteatoma: facial palsy, gradually progressive hearing loss, and chronic draining of the right ear.
  • Other objective findings also supported a finding of cholesteatoma, but a computed tomographic scan and magnetic resonance imaging scan showed a well-enhanced mass and extensive bony erosion in the middle ear.
  • At surgery, a granulous tumor in the mastoid cavity was diagnosed as squamous cell carcinoma, and closely coexisting cholesteatoma was found.
  • Surgical specimen demonstrated carcinoma and cholesteatoma in the same field.
  • INTERVENTION: Radiation and chemotherapy were performed followed-up by mastoidectomy.
  • CONCLUSION: Because middle ear carcinoma has a poor prognosis, it is important to detect lesions early.
  • It is necessary to consider that middle ear carcinoma arises from not only chronic otitis media or surgical invasion but also from primary acquired cholesteatoma.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Cell Transformation, Neoplastic / pathology. Cholesteatoma, Middle Ear / diagnosis. Ear Neoplasms / diagnosis. Ear, Middle. Magnetic Resonance Imaging. Mastoid. Skull Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Otoscopy

  • Genetic Alliance. consumer health - Cholesteatoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699729.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Ogawa K, Nakamura K, Hatano K, Uno T, Fuwa N, Itami J, Kojya S, Nakashima T, Shinhama A, Nakagawa T, Toita T, Sakai M, Kodaira T, Suzuki M, Ito H, Murayama S: Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1326-34
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients.
  • PURPOSE: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear.
  • METHODS AND MATERIALS: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed.
  • Chemotherapy was administered in 34 patients (39%).
  • On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS.
  • On multivariate analysis, T stage and treatment modality were significant prognostic factors.
  • Chemotherapy did not influence DFS.
  • CONCLUSIONS: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease.
  • Further clarification on the role of chemotherapy is necessary.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Ear Canal. Ear Neoplasms / therapy. Ear, Middle
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Relative Biological Effectiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446002.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 95 cases of squamous cell carcinoma of the external and middle ear.
  • OBJECTIVE: To analyze the clinical characteristics, 5-year survival, and prognostic factors of squamous cell carcinoma (SCC) of the external and middle ear.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • SCC located in the external ear could be detected in an earlier stage than that in the middle ear.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • CONCLUSION: Local infiltration seems to be the main behavior of SCC in the external and middle ear.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Ear Neoplasms / epidemiology. Ear, External. Ear, Middle
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Earache. Facial Paralysis. Female. Hearing Loss. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Survival Analysis. Temporal Bone / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Chan SW, Mukesh BN, Sizeland A: Treatment outcome of N3 nodal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg; 2003 Jul;129(1):55-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
  • OBJECTIVE: The aim of this study was to investigate the treatment outcome of N3 nodal disease.
  • A total of 53 patients with primary presentation of squamous cell carcinomas from various head and neck sites from 1980 to 1994 were recruited for this study.
  • Eight patients with nasopharyngeal cancers who underwent treatment with palliative intent were excluded from the study.
  • Treatment options were broadly divided into 4 treatment categories; postoperative radiotherapy; preoperative radiotherapy; surgery alone; and chemotherapy pre- or postoperatively with or without radiotherapy.
  • Of the 45 N3 patients, 21 patients had a recurrence in the neck after treatment, with 1 in the contralateral neck.
  • CONCLUSION: Our treatment outcomes, particularly those in the group receiving postoperative radiotherapy, were similar to other studies.
  • The role of definitive chemotherapy and/or radiotherapy and salvage surgery is difficult to evaluate as the results are inconsistent and the available data are limited.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neck Dissection / methods. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12869917.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Ogino S, Iino Y, Nakamoto Y, Murakami Y, Toriyama M: [Histopathological study of the temporal bones in patients with primary carcinomas of the ear]. Nihon Jibiinkoka Gakkai Kaiho; 2000 Oct;103(10):1141-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological study of the temporal bones in patients with primary carcinomas of the ear].
  • The most common symptoms of patients with carcinomas of the middle ear or mastoid are otorrhea, facial paralysis, and hearing loss, including a sensorineural element and vertigo.
  • The latter two symptoms are indicators of inner ear damage.
  • However, few reports have been made concerning the histopathological changes that occur in the inner ear in the presence of a tumor.
  • The present study was performed to determine the pattern of tumor invasion in the inner ear and the histopathological changes that occur in the inner ear in cases of ear carcinomas.
  • Temporal bone sections from five patients (age: #39-73 years; 3 males and 2 females) who died from a primary carcinoma of the ear were studied histologically.
  • 1) localization of the tumor in the temporal bone, 2) pattern of tumor invasion in the inner ear, 3) pathological changes in the inner ear, including the cochlea, vestibule and semicircular canals.
  • Tumor cells were still present in the temporal bone sections of all the patients except one, even though the patients had received various treatments for the carcinoma, including radiation therapy, surgery and chemotherapy.
  • Marked inflammatory and necrotic changes were observed in cases where the tumor had invaded the external auditory canal, middle ear cleft, internal auditory canal, and in some cases the inner ear.
  • In cases where the tumor invaded the inner ear via the internal auditory canal rather than directly from the middle ear, the otic capsule is thought to have acted as a barrier against tumor invasion.
  • In addition, marked degenerative changes throughout the entire inner ear structures were noted.
  • These changes may have arisen from an attenuated blood supply to the inner ear as a result of pressure from the tumor in the internal auditory canal, tumor infiltration of the labyrinthine artery.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ear Neoplasms / pathology. Ear, Inner / pathology. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109823.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


11. Gourin CG, Johnson JT: Surgical treatment of squamous cell carcinoma of the base of tongue. Head Neck; 2001 Aug;23(8):653-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of squamous cell carcinoma of the base of tongue.
  • INTRODUCTION: Squamous cell carcinoma (SSC) of the tongue base has historically been shown to be associated with a poor prognosis.
  • We reviewed our experience with primary surgery followed by postoperative radiation therapy (XRT) to determine the impact of our treatment protocols on outcome.
  • Adjuvant chemotherapy was offered if histologic signs of aggressive behavior were identified (multiple nodes or extracapsular spread).
  • Local recurrence occurred in 5 patients, regional recurrence occurred in 12 patients, and distant metastases developed in 22 patients.
  • CONCLUSIONS: Surgical treatment of SCC of the tongue base is highly effective in achieving local disease control and disease-free survival for early lesions.
  • Because both functional outcome and survival are poor after surgical treatment of advanced lesions, we now offer brachytherapy with XRT or participation in a combined chemoradiation protocol rather than primary surgical therapy to patients with advanced disease.
  • Prospective studies are needed to compare the effect of these organ-preserving therapies with traditional combined surgery and XRT to determine the effect on functional outcome and quality of life.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Tongue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glossectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11443748.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Chee G, Mok P, Sim R: Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis. Singapore Med J; 2000 Sep;41(9):441-6, 451
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis.
  • Squamous cell carcinoma of the external ear canal is an uncommon condition that is associated with a poor outcome.
  • The development of an accepted staging system has not been forthcoming and this has inhibited the formation of an evidence-based therapeutic protocol.
  • We report the findings in 14 patients with squamous cell carcinoma of the external ear canal treated in our institutions.
  • Four patients had a history of chronic ear discharge and one had previous radiotherapy for nasopharyngeal carcinoma.
  • With combination treatment involving surgery, radiotherapy and chemotherapy, disease free survival achieved was 69% (9 of 13) over a mean follow-up period of 24.7 months.
  • One patient absconded treatment.
  • [MeSH-major] Carcinoma, Squamous Cell. Skull Neoplasms. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193117.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


13. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene; 2005 Jun 23;24(27):4442-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
  • Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy.
  • Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined.
  • Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens.
  • Pharmacological doses of EPO also had a limited proliferation effect in these cell lines.
  • These results define a novel role for EPO in mediating tumor cell invasion.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Erythropoietin / pharmacology. Head and Neck Neoplasms / metabolism. Milk Proteins / metabolism. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Signal Transduction / drug effects. Trans-Activators / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Cell Proliferation / drug effects. Enzyme Activation / drug effects. Female. Humans. Janus Kinase 2. Male. Middle Aged. Mutation / genetics. Neoplasm Invasiveness. Protein Kinase Inhibitors / pharmacology. Receptors, Erythropoietin / metabolism. STAT5 Transcription Factor. Tyrphostins / pharmacology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2005 Dec 8;24(55):8216
  • (PMID = 15856028.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / T32 DC000066-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Milk Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Erythropoietin; 0 / STAT5 Transcription Factor; 0 / Trans-Activators; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 11096-26-7 / Erythropoietin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


14. Ueda Y, Kurita T, Matsuda Y, Ito S, Nakashima T: Superselective, intra-arterial, rapid infusion chemotherapy for external auditory canal carcinoma. J Laryngol Otol Suppl; 2009;(31):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective, intra-arterial, rapid infusion chemotherapy for external auditory canal carcinoma.
  • Previously, the treatment of carcinoma of the external auditory canal has mainly involved surgical resection.
  • In order to enable organ preservation and to obtain cancer-free surgical margins, we introduced the use of superselective, intra-arterial, rapid infusion chemotherapy combined with radiotherapy to treat this condition.We reviewed our patients' tumour stages, feeding arteries and clinical outcomes.
  • Chemotherapy was administered intra-arterially in the angiography suite via transfemoral catheterisation of the feeding arteries.
  • The overall toxic side effects were modest.Superselective, intra-arterial, rapid infusion chemotherapy can be an effective, organ-preserving treatment for external auditory canal carcinoma, with a high cure rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Ear Canal. Ear Neoplasms / drug therapy. Infusions, Intra-Arterial / methods
  • [MeSH-minor] Aged. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460210.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Joo J, Sercarz JA, Paolini AA, Castro DJ, Paiva MB: Laser-induced thermal therapy and cisplatin for recurrent head and neck cancer: a case characterized by an unusually long disease-free survival. Ear Nose Throat J; 2009 Nov;88(11):E13-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser-induced thermal therapy and cisplatin for recurrent head and neck cancer: a case characterized by an unusually long disease-free survival.
  • Recurrent squamous cell carcinoma after major surgery and microvascular reconstruction with a free-flap transfer is difficult to handle via conventional treatment methods.
  • Based on our experience with laser-induced thermal therapy for recurrent head and neck tumors, we explored an aggressive treatment protocol using laser thermal ablation with concurrent cisplatin chemotherapy as a minimally invasive option for the treatment of a patient with recurrent squamous cell carcinoma of the neck who had previously undergone a reconstructive free-flap transfer.
  • Because of the very favorable outcome we observed in this patient with this combined treatment modality, we report this case, and we review some aspects of the treatment proposed.
  • The remarkable survival of this patient suggests that the combination of laser-induced thermal therapy and chemotherapy warrants further investigation as an alternate treatment for patients with recurrent head and neck cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924650.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA131509; United States / NCI NIH HHS / CA / K22 CA131509-01
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM: Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg; 2004 Apr;30(4 Pt 2):674-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma.
  • OBJECTIVES: This study aimed to determine the effect of significantly reducing or stopping immunosuppressive therapy on prognosis of aggressive squamous cell carcinomas (SCC) in renal transplant recipients (RTRs).
  • PATIENTS/METHODS: Retrospective study of nine patients with aggressive SCC identified two groups, one whose immunosuppressive therapy was not altered and the other who had their therapy stopped or significantly reduced.
  • RESULTS: Aggressive SCC all occurred on the head and neck, with five of the primary tumors originating from the ear.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Immunosuppressive Agents / immunology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Humans. Kidney Transplantation / adverse effects. Kidney Transplantation / immunology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Pilot Projects. Prognosis. Retrospective Studies


17. Sumitsawan Y, Chaiyasate S, Chitapanarux I, Anansuthiwara M, Roongrotwattanasiri K, Vaseenon V, Tooncam H: Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Apr;36(2):205-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late complications of radiotherapy for nasopharyngeal carcinoma.
  • The mean pre- and post-treatment body mass indexes (BMI) were 22.5+/-4 (15-35.6), and 19.8+/-3.2 (12.9-34.5; P<0.05).
  • Most of the patients (92%) had undifferentiated (50.5%) and poorly differentiated (41.5%) squamous cell carcinoma.
  • Chemotherapy was given to 145 patients (72.5%).
  • The mean post-radiation period in the added chemotherapy group was lower than the group treated with radiation alone (2.9+/-2.7 years vs. 5.4+/-4.4 years, P<.05).
  • The most common complication was dryness of mouth (97.5%); followed by hearing impairment (inner ear 82.5%).
  • Added chemotherapy increased the complication severity significantly for the skin (P<0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Quality of Life. Radiotherapy Dosage. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635325.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Garandawa HI, Ahmad BM, Nggada HA: Nasopharyngeal cancer in North--Eastern Nigeria: clinical trends. Niger J Clin Pract; 2009 Dec;12(4):379-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine prevalence, clinical trends and histopathological types of Nasopharyngeal cancer in Maiduguri, North Eastern Nigeria.
  • RESULTS: Nasopharyngeal cancers constituted 35.1% of all malignancies of ear, nose, throat during the study period.
  • The commonest histological type was squamous cell carcinoma(92.5%).
  • Patients who received chemotherapy in addition to radiotherapy and higher symptom free period.
  • A meticulous ear, nose and throat examination and thorough evaluation of nasal symptoms with associated cervical lymphadenopathy may lead to an early diagnosis of nasopharyngeal cancer's.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Nasopharyngeal Neoplasms / epidemiology. Rhabdomyosarcoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Prevalence. Registries. Retrospective Studies. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329676.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


19. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ: Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1320-5
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cisplatin chemo-irradiation is increasingly used in locally advanced squamous cell carcinoma of the head and neck.
  • METHODS AND MATERIALS: A prospective analysis of hearing thresholds at low and (ultra) high frequencies obtained before, during, and after treatment in 146 patients.
  • Treatment consisted of intra-arterial infusion of high-dose cisplatin (150 mg/m(2), four courses) with sodium thiosulfate rescue and concurrent radiation therapy (70 Gy).
  • RESULTS: After treatment, 23% of the ears were under consideration for hearing aids because of therapy.
  • Twenty-two percent of the patients developed an increase in air-bone gap >10 dB during or after therapy.
  • In the multivariate explanatory analysis, cumulative dose of cisplatin and radiation therapy, and young age displayed a causal relationship with increased sensorineural hearing loss during and after therapy (p < 0.001).
  • In the multivariate prediction analysis, pretreatment hearing level of the concerning ear was identified as an independent predictive factor for hearing capability after therapy (p < 0.0001).
  • CONCLUSIONS: Both cisplatin and radiation therapy were proven to induce sensorineural hearing loss, in this study with short-term follow-up.
  • Of all patient and treatment variables studied, the patients pretreatment hearing level appeared to be the main predictive factor for hearing capability after high-dose intra-arterial cisplatin chemoradiation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / therapy. Cisplatin / adverse effects. Head and Neck Neoplasms / therapy. Hearing Loss, Sensorineural / etiology
  • [MeSH-minor] Age Factors. Antidotes / therapeutic use. Combined Modality Therapy / methods. Female. Hearing / drug effects. Hearing / radiation effects. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Radiation Dosage. Risk Factors. Thiosulfates / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418969.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antineoplastic Agents; 0 / Thiosulfates; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • PURPOSE: To address the following questions: which parameters influenced the frequency of distant metastases in patients with locally advanced ear-nose-throat (ENT) tumors, which was the distribution pattern of metastases, and what were the diagnostic consequences for pretherapeutic staging?
  • PATIENTS AND METHODS: 600 patients (526 men, 76 women, median age 56 years) with ENT tumors (squamous cell carcinoma histology) were studied retrospectively.
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Falcioni M, Piccirillo E, Di Trapani G, Romano G, Russo A: Internal auditory canal metastasis. Acta Otorhinolaryngol Ital; 2004 Apr;24(2):78-82
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since pre-operative diagnosis is fundamental in the planning of a correct therapeutic strategy, it is important that the neurotologist be aware of the possibility of their occurrence in this particular area.
  • Correct pre-operative diagnosis is particularly difficult in patients in whom the primary tumour has not been detected at the time of identification of the lesion in the internal auditory canal.
  • On the contrary, in cases of a single metastasis, both magnetic resonance imaging and computed tomography usually fail to show any distinctive feature when compared to the most common tumours of the internal auditory canal (vestibular schwannomas and meningiomas).
  • Bilateral metastases can also be misdiagnosed as neurofibromatosis type 2.
  • Radiotherapy and/or chemotherapy are the two main treatment modalities, while surgical removal is reserved for selected cases of a single metastasis.
  • Albeit, due to the paucity of specific radiological and clinical characteristics, surgical removal is often necessary to reach the correct diagnosis, as occurred in 2 of the present patients.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Cranial Nerve Neoplasms / secondary. Ear Neoplasms / secondary. Facial Nerve. Lung Neoplasms. Prostatic Neoplasms. Uterine Neoplasms. Vestibulocochlear Nerve. Vestibulocochlear Nerve Diseases
  • [MeSH-minor] Aged. Biopsy. Cerebellopontine Angle. Diagnosis, Differential. Female. Follow-Up Studies. Gadolinium. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15468996.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


22. Stranzl H, Gabor S, Mayer R, Prettenhofer U, Wurzinger G, Hackl A: Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries. Strahlenther Onkol; 2002 Aug;178(8):442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
  • PATIENTS AND METHOD: Between 1991 and 1998, eleven patients (female n = 3, male n = 8; age: median 66 years, range 44-81 years) underwent intraluminal HDR brachytherapy for histologically confirmed endobronchial metastases from non-pulmonary primary tumors of various sites like urogenital tract (n = 5), gastrointestinal tract (n = 3), ear/nose/throat (n = 2) and breast (n = 1).
  • The median time between diagnosis of the primary non-bronchogenic tumor and histopathological diagnosis of the endobronchial metastases was 39 months, range 1-99 months.
  • A total dose of 15-20 Gy was delivered in three to four fractions of 5-6 Gy once a week.
  • No palliative chemotherapy was added.
  • Treatment was judged unsuccessful in three (27%) patients.
  • The applied treatment is a safe, effective and well tolerated palliative procedure leading to an improved patient quality of life.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms. Carcinoma, Renal Cell / radiotherapy. Carcinoma, Renal Cell / secondary. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / secondary. Dose Fractionation. Female. Follow-Up Studies. Humans. Kidney Neoplasms. Male. Middle Aged. Palliative Care. Prostatic Neoplasms. Radiotherapy Dosage. Rectal Neoplasms. Sigmoid Neoplasms. Time Factors. Tongue Neoplasms. Tonsillar Neoplasms. Urinary Bladder Neoplasms. Uterine Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12240550.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


23. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


24. Jelić S, Stamatović Lj, Vucićević S, Petrović Z, Kreacić M, Babović N, Jovanović N, Mikić A, Gavrilović D: Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients. Eur J Cancer; 2002 Jul;38(11):1478-89
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this open, prospective, randomised study was to estimate the eventual benefits from the inclusion of high-dose cytarabine in the cisplatin-5-fluorouracil (5-FU) regimen as first-line treatment of patients with advanced head and neck cancer.
  • The study recruited successive patients with unresectable grade I/II head and neck cancer who were not suitable for irradiation treatment (T any N3 or T4 N2C), metastatic or previously irradiated.
  • A joint ear, nose and throat (ENT) oncological committee performed the selection.
  • The proportion of patients from the appropriate subset who achieved a clinical response making additional treatment feasible was higher in arm A (P=0.00015), as well as the proportion of patients with a performance status 2+3 achieving a response (P<0.0001).
  • Due to its haematological side-effects, cytarabine might not be the ideal drug to modulate the cytotoxicity of cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Synergism. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110494.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA: Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Cancer Invest; 2006 Mar;24(2):164-73
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
  • PURPOSE: Phase I study to determine the maximally tolerated dose (MTD) of cisplatin (cDDP), paclitaxel (P), and concurrent split course hyperfractionated (BID) RT in advanced squamous cell carcinoma of the head and neck (SCCHN) and other upper aerodigestive tumors.
  • Previously radiated patients received 150 cGy bid x 5, wk 1; then 120 cGy bid x 5 Q 2 wk x 3 (later increased to 150 cGy BID for the entire treatment).
  • Treatment fields included recurrent tumor only with 2 cm margins.
  • Granulocyte colony stimulating factor (G-CSF) days 6-12 (off treatment week) was added if cumulative neutropenia precipitated treatment delays.
  • Eight had received prior chemotherapy, 27 prior RT.
  • At dose level three, regular treatment delays of >or=1 week due to slow neutrophil recovery occurred.
  • Addition of G-CSF (dose level 3b) reduced treatment delays from 100 percent to 28 percent and decreased the incidence of Grade >or=2 neutropenia and mucositis.
  • Six of 7 patients at this dose level completed all 4 cycles of treatment and all received full dose RT (60 Gy).
  • Median time to progression in this group was 6 months, with median and one-year survival of 9.5 mos and 41 percent, respectively.
  • CONCLUSION: Concurrent daily cisplatin/paclitaxel and split course hyperfractionated RT (60 Gy) is feasible in previously radiated patients.
  • G-CSF, administered between each cycle, reduces the incidence of treatment delays.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Dose Fractionation. Head and Neck Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Drug Administration Schedule. Ear Neoplasms / mortality. Ear Neoplasms / therapy. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Recombinant Proteins. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537186.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Völter C, Baier G, Hoppe F, Schwager K, Helms J: [Diagnosis, treatment and results of malignant skull base tumours]. Laryngorhinootologie; 2001 Sep;80(9):512-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis, treatment and results of malignant skull base tumours].
  • [Transliterated title] Diagnostik, Therapie und Ergebnisse in der Behandlung maligner Schädelbasistumoren1.
  • Most of the tumours (n = 51) originated from the nose or paranasal sinuses, the epipharynx, the outer ear canal or the middle ear.
  • The histological diagnosis was confirmed in 53 patients preoperatively and in seven patients during tumour resection.
  • Squamous cell carcinoma (n = 24), adenocarcinoma (n = 10) and sarcoma (n = 7) were the most common histologies found.
  • A surgical tumour reduction with postoperative radiation therapy was performed in seven patients as a palliative approach.
  • Eight patients underwent a combined radio- and chemotherapy according to the histological diagnosis.
  • Primary radiotherapy was the treatment of choice in eleven patients, where the tumours were located in the central area of the cranial base.
  • DISCUSSION: A statistical analysis of the results is not applicable due to the great variety of the disease concerning the histological diagnosis, the tumour size and the location as well as the small number of patients.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Esthesioneuroblastoma, Olfactory. Sarcoma. Skull Base Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Palliative Care. Postoperative Complications. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11555782.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Karaman E, Duman C, Mercan H, Ozaras R, Cansız H: Relapsing deep neck infection may indicate a coexisting esophagus cancer. Kulak Burun Bogaz Ihtis Derg; 2009 Mar-Apr;19(2):103-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This presentation leads to delay of the diagnosis of underlying cancer.
  • We report a case with relapsing deep neck infection who was diagnosed as proximal esophagus squamous cell carcinoma thereafter.
  • [MeSH-major] Abscess / etiology. Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Infection / diagnosis
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Cephalosporins / therapeutic use. Cervical Vertebrae / radiography. Female. Humans. Klebsiella Infections / diagnosis. Klebsiella Infections / drug therapy. Middle Aged. Necrosis. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abscess.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796009.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins
  •  go-up   go-down


28. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down






Advertisement